Why the study?
Understanding and management of mitral regurgitation have evolved substantially, with safe and effective percutaneous mitral valve interventions expanding therapeutic options for inoperable or high surgical risk patients.
This review highlights the safety, efficacy, and expanding indications of transcatheter edge-to-edge repair for patients with severe mitral regurgitation who are not optimal surgical candidates.
Transcatheter mitral interventions expand options for high-risk patients; leaves open optimal selection and durability questions.
Purpose of review In recent years, our understanding of mitral regurgitation and its management has evolved substantially. In particular, as percutaneous mitral valve interventions have proven safe and effective, it has become possible to offer expanded therapeutic options to patients who are deemed inoperable or at high surgical risk. This review provides an overview of currently available transcatheter mitral valve interventions and summarizes recently published findings that may allow for better risk stratification, patient selection, and procedural safety and efficacy. Recent findings In the last 1–2 years, numerous studies have provided important insights that help to better characterize patients in clinical practice and to select them more optimally for specific interventional mitral valve procedures. Summary The evolution of percutaneous MV therapy has been substantial and extremely beneficial for patient care. Nonetheless, this is an area underdevelopment and newer or enhanced devices are likely to emerge in the future.
No takes yet. Share an insight, caveat, or question.
Wunderlich et al. (2023) conducted a review in Mitral Regurgitation. Percutaneous mitral valve interventions (M-TEER) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: